Results 61 to 70 of about 14,813,386 (261)

K12-ligand-based CAR T cell therapy for CD7-positive T cell malignancies

Molecular Therapy: Oncology
Chimeric antigen receptor (CAR)-based therapy is of interest for relapsed or refractory (r/r) T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas. A prominent target antigen for this is the receptor CD7, which is expressed in ∼95% of T-ALL, ∼
Nienke Visser, Macarena González-Corrales, Jimena Álvarez-Freile, Maurien G. Pruis, Lena Rockstein, Harm Jan Lourens, Jan Jacob Schuringa, Tom van Meerten, Gerwin Huls, Edwin Bremer   +9 more
doaj   +1 more source

Early preclinical development of a CAR-T cell approach targeting novel antigens associated to pediatric acute myeloid leukemia

, 2022
reservedINTRODUZIONE La leucemia acuta mieloide (LAM) rimane ancora oggi una sfida per quanto riguarda il trattamento. Inoltre, le forme refrattarie e recidivanti ne sono la causa principale di mortalità.
MARTINI, ALBERTO
core  

Partial depletion of plasminogen activator inhibitor‐1 decreases subcutaneous fat cell hypertrophy and liver cholesterol in high‐fat‐fed female mice

FEBS Letters, EarlyView.
Obesity raises blood levels of PAI‐1, a protein linked to metabolic dysfunction‐associated steatotic liver disease in people with obesity. In female mice fed a high‐fat diet, partially lowering PAI‐1 led to smaller subcutaneous fat cells and lower liver cholesterol, without changing body weight or insulin sensitivity.
Claudia E. Ramirez Bustamante, Robert Sharp, Pradip K. Saha, Elizabeth S. Anaya, Elizabeth L. Lieu, Evelyn L. de Groot, Pooja Patel, Mi Jeong Heo, Aaron R. Cox, Kang Ho Kim, Sean M. Hartig   +10 more
wiley   +1 more source

Glycan-directed CAR-T cells [PDF]

Glycobiology, 2018
Cancer immunotherapy is rapidly advancing in the treatment of a variety of hematopoietic cancers, including pediatric acute lymphoblastic leukemia and diffuse large B cell lymphoma, with chimeric antigen receptor (CAR)-T cells. CARs are genetically encoded artificial T cell receptors that combine the antigen specificity of an antibody with the ...
Steentoft, Catharina, Migliorini, Denis, King, Tiffany R, Mandel, Ulla, June, Carl H, Posey, Avery D   +5 more
openaire   +3 more sources

Single-cell analysis of the survival mechanisms of fratricidal CAR-T targeting of T cell malignancies

Molecular Therapy: Nucleic Acids
Chimeric antigen receptor T (CAR-T) cell therapy targeting T cell tumors still faces many challenges, one of which is its fratricide due to the target gene expressed on CAR-T cells.
Hui Hu, Ling Tang, Yuyan Zhao, Jiali Cheng, Mei Huang, Yong You, Ping Zou, Qian Lei, Xiaojian Zhu, An-Yuan Guo   +9 more
doaj   +1 more source

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The Netherlands [PDF]

, 2023
The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries.
Dutch CAR-T Tumorboard Consortium
core  

From junk to function — How weak selection in eukaryotes builds new parts and drives genomic complexity

FEBS Letters, EarlyView.
How do genomes gain new functional parts? In eukaryotes, which tend to evolve under weak selection, much of the genome is junk. Palazzo and Qiu borrow the logic of Markov chains to show how non‐functional DNA becomes functional through the appearance of intermediate states, which arise due to epistasis, buffering, and biochemical messiness, allowing ...
Alexander F. Palazzo, Yi Qiu
wiley   +1 more source

CD19 CAR T Cells

Cell, 2017
CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient ...
openaire   +2 more sources

Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases

Frontiers in Bioscience-Landmark
Anticancer therapeutics have evolved from small-molecule drugs to monoclonal antibodies and, more recently, to cell and gene therapies (CGTs). This progress has been driven by the pursuit of greater drug specificity, potency, and safety.
Daekee Kwon, Kyung-Sun Kang
doaj   +1 more source

The Shewanella oneidensis Fic enzyme SoFic targets the switch‐I region of EF‐Tu for AMPylation

FEBS Letters, EarlyView.
Fic enzymes mediate diverse post‐translational modifications across all domains of life, including AMPylation. Prokaryotic EF‐Tu can be AMPylated and deAMPylated by the conserved Fic enzyme SoFic. Structural and biochemical approaches were used to characterize the effect of AMPylation on EF‐Tu, SoFic's enzymatic activities, and the enzyme‐target ...
Svenja Runge, Vivian Pogenberg, Alexander Baumgart, Bente Siebels, Hartmut Schlüter, Michael Hecht‐Bucher, Aymelt Itzen   +6 more
wiley   +1 more source